Neonatal Formulations: The Need for a Tailored, Knowledge Driven Approach

Area of Science:

• Neonatal pharmacotherapy
• Pediatric clinical pharmacology
• Drug formulation development

Background:

• Neonates exhibit low and highly variable drug clearance compared to other pediatric groups.
• Effective and safe pharmacotherapy in neonates necessitates consideration of clinical factors and pharmacokinetics.
• Current knowledge on excipient safety and toxicity in neonates is limited and difficult to access.

Purpose of the Study:

• To highlight the need for tailored drug product development in neonates.
• To emphasize the importance of addressing excipient exposure and safety.
• To advocate for improved compounding practices for neonatal drug formulations.

Main Methods:

• Review of existing knowledge on neonatal pharmacokinetics and excipient safety.
• Discussion of initiatives like the Safety and Toxicity of Excipients for Pediatrics (STEP) database.
• Highlighting feasibility studies such as the propylene glycol research project and the European Study for Neonatal Excipient Exposure (ESNEE).

Main Results:

• Neonates require drug formulations with low and flexible dosing capabilities due to variable clearance.
• There is a critical need for improved guidance and research on excipient safety in neonatal populations.
• Current compounding practices require evaluation to ensure safety, stability, and accurate dosing.

Conclusions:

• Tailored drug formulations are essential for safe and effective neonatal pharmacotherapy.
• Further research and initiatives are needed to establish excipient safety profiles for neonates.
• Pharmacists require support and evaluation of compounding practices to optimize neonatal drug administration.